Orientation Before Reading
Critical Axes and Publication Limits
- Article type: Intervention. The topic is structured around three clinical decision axes, not a global judgment.
- Evidence base: Evidence level B, moderate strength of conclusion, 4 retrospective cohort studies. No RCT or meta-analysis available.
- Bias risk: moderate (4/4 yellow). CoI risk: not systematically reported. Source integrity: clean after Stage-3 cleanup.
- Long-term data >5 years are largely absent. Reported survival rates stem from highly selective study populations.
Clinical Question
What is the survival rate of a second implant placed at a previously failed site — and which factors determine whether re-implantation is preferable to conventional prosthetic restoration?
Executive Summary
The available evidence on re-implantation at previously failed sites rests on four retrospective cohort studies (Mardinger 2012, Chrcanovic 2017, Chatzopoulos 2024, Guezel 2025). No randomized controlled trials or meta-analyses exist for this specific clinical question. [1–4]
DDJ reads the evidence body as moderately sound: the direction supports a conditional clinical benefit of re-implantation in selected cases. Major limitations include absent long-term data, highly selective populations, and the lack of standardized selection criteria in guidelines. [1–4]
Three clinical decision axes structure the analysis: the achievable survival rate, prognostically relevant risk factors, and the trade-off against conventional alternatives. None of these axes currently allows a blanket judgment.
How DDJ Reads This Topic
Re-implantation after implant loss is not a routine indication, even as the technique has become increasingly standardized. The core clinical question shifts from "Can we re-implant?" to "Should we re-implant — and if so, under what conditions?"
DDJ treats this topic as an intervention article. This means: individual axes are first assessed, and then a differentiated overall reading is constructed from them. A simple yes or no on re-implantation does not reflect clinical reality.
The Stage-3 cleanup removed 5 off-topic PMIDs from the original corpus (general implant literature without specific relevance to re-implantation following explantation). The remaining 4 studies are thematically precise but methodologically limited. [1–4]
Claim Clusters and Decision Axes
Claim Cluster 1 · ddj_0013_c01
Survival Rates of Re-Implantation
Clinical Axis: How reliably does a second implant survive at a failed site?
Why This Axis Matters: The decision for or against re-implantation depends primarily on the expected prognosis. Without reliable survival rates, treatment planning remains speculative.
Evidence: Four retrospective cohort studies report survival rates of second implants placed at previously failed sites. Short-term outcomes are acceptable but tend to be lower than survival rates of primary implants in comparable locations. [1–4]
Where the Signal Is Stable: In selected cohorts with adequate bone quality and an identified cause of primary failure, second implants show acceptable short-term survival (up to approximately 3–5 years). Chrcanovic et al. 2017 provide the largest cohort with longer-term follow-up and support this assessment. [2]
Where Uncertainty Begins: Long-term data beyond 5 years are sparse. Study populations are highly selective — patients with poor baseline conditions are frequently not re-implanted and therefore do not appear in survival statistics. This selection bias overestimates the actual success rate in the overall population. [1–4]
Clinical Consequence: Re-implantation is not a standard procedure. Reported survival rates apply only to carefully selected cases and must not be extrapolated to all patients experiencing implant loss.